Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer

Table 2

HIV-related markers while on immune checkpoint inhibitor therapy.

Patient	HAART regimen	CD 4 (cells/l) at baseline	CD 4 (cells/l) at 12 weeks	VL (copies/ml) at baseline	VL (copies/ml) at 12 weeks
1	FTC/TDF + DTG	573	NA	0	NA
2	EVG/c/FTC/TDF	242	NA	<400	NA
3	DTG, DRV/r	795	552	<400	0
4	ABC/DTG/3TC	424	460	0	0
5	FTC/TDF + DTG	427	402	0	<400
6	FTC/TDF + DRV	626	517	0	0
7	ETR, DTG, DRV/r	607	597	<20	<20
8	EFV/FTC/TDF	305	NA	<20	NA
9	FTC/TAF + DTG	NA	NA	NA	NA
10	RPV/FTC/TDF	469	NA	<20	NA
11	FTC/TDF + DTG	624	NA	500	NA
12	ABC/3TC/DTG	250	262	<20	<20
13	FTC/TDF + DTG	326	431	0	0
14	FTC/TDF + DTG	150	120	<20	<20
15	TDF/RAL	461	376	<400	<400
16	DRV/c + DTG	163	285	89	<20
17	FTC/TDF + DTG	264	370	0	<400

Abbreviations: NA: data not available. : died before response could be assessed. VL: viral load.
HAART regimen: FTC/TDF: emtricitabine/tenofovir disoproxil fumarate. DTG: dolutegravir. EVG/c: elvitegravir/cobicistat. DRV/r: darunavir/ritonavir. ABC: abacavir. 3TC: lamivudine. TDF: tenofovir disoproxil fumarate. RAL: raltegravir. DRV/c: darunavir. ETR: etravirine. EFV: efavirenz. TAF: tenofovir alafenamide. RPV: rilpivirine.